CagriSema combines two different appetite-regulating hormones in one weekly shot. Phase 3 produced 22.7% body weight loss, and the FDA is currently reviewing it for approval.
One shot that combines Wegovy's active ingredient with a second hunger hormone your body naturally makes. Most weight loss drugs attack hunger from one angle. CagriSema attacks it from two at once, and those two angles work differently enough that combining them produces something meaningfully stronger than either drug on its own.
A single subcutaneous pen injection, similar to Wegovy or Ozempic. You inject into your stomach, thigh, or upper arm. The dose starts low and increases gradually over about 16 weeks to reduce side effects.
Semaglutide activates GLP-1 receptors in your brain, reducing hunger and slowing digestion. Cagrilintide activates amylin receptors through a completely different pathway. Both signals arrive at once, creating a stronger suppression of appetite than either achieves alone.
People on CagriSema in clinical trials described the same "food noise goes quiet" effect reported with Wegovy, but more pronounced. Portions shrink naturally, cravings ease, and the physical sensation of fullness arrives sooner during meals.
REDEFINE 1 showed 22.7% average weight loss. 60% of participants lost 20% or more. The REDEFINE trial program ran two large Phase 3 studies across thousands of participants. REDEFINE 1 enrolled adults with obesity or overweight without type 2 diabetes. REDEFINE 2 enrolled adults who also had type 2 diabetes. Both trials ran 68 weeks.
The most common side effects were gastrointestinal, nausea, vomiting, diarrhea, and constipation, affecting about 79.6% of CagriSema patients versus 39.9% on placebo. The key context: these effects were mainly mild to moderate and most were temporary, peaking during the dose-escalation phase and settling down as the body adjusts. This side-effect pattern is similar to other GLP-1 drugs like Wegovy. No new or unexpected safety signals emerged in the trials.
NDA filed Dec 2025 · Decision ~Oct 2026. FDA decision expected late 2026. CagriSema is ahead of virtually every other drug in the obesity pipeline. Both Phase 3 trials are complete, the application is filed, and the FDA is reviewing it now. A look at how it got here.
"Adding amylin to semaglutide sounds logical on paper. The question is always whether you get real additive benefit or just more side effects. The early cagrisema data leans toward actual benefit, which is encouraging, but I'll want to see it hold up."
Dr. Humberto Fernandez-Miro, MD
Family Medicine · Clinical Research
Strong fit for people who want the maximum proven weight loss from an injectable drug. CagriSema targets the same general population as Wegovy and other GLP-1 drugs, but it's engineered to go further. The trial data tells a specific story about who benefits most.
CagriSema vs approved drugs and the other leading pipeline medication.
| Drug | Weight Loss | Mechanism | Form | Status |
|---|---|---|---|---|
| 💉CagriSema You're here |
22.7% (Ph3) | GLP-1 + Amylin | Weekly injection | FDA Review |
| 💉Retatrutide | 24% (Ph2) | Triple Agonist | Weekly injection | Phase 3 |
| 💉Zepbound | 21% | Dual Agonist (GLP-1, GIP) | Weekly injection | ✓ Approved |
| 💉Wegovy | 15% | GLP-1 Agonist | Weekly injection | ✓ Approved |
| 💊Foundayo | 12% | GLP-1 Agonist | Daily pill | ✓ Approved |
Phase 2 and Phase 3 numbers are from clinical trials, not direct drug-to-drug comparisons. Interpret any cross-trial numbers carefully.